Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Accenture
Covington
Teva
Federal Trade Commission
Farmers Insurance
Fuji
US Army
Dow
Harvard Business School

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,665,772

« Back to Dashboard

Which drugs does patent 5,665,772 protect, and when does it expire?

Patent 5,665,772 protects AFINITOR DISPERZ, AFINITOR, and ZORTRESS, and is included in three NDAs.

Protection for AFINITOR DISPERZ has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
Summary for Patent: 5,665,772
Title: O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
Abstract:Novel derivatives of rapamycin, particularly 9-deoxorapamycins, 26-dihydro-rapamycins, and 40-0-substituted and 28,40-0,0-di-substituted rapamycins, are found to have pharmaceutical utility, particularly as an immunosuppressants.
Inventor(s): Cottens; Sylvain (Witterswil, CH), Sedrani; Richard (Basel, CH)
Assignee: Sandoz Ltd. (Basel, CH)
Application Number:08/416,673
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 5,665,772

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharm AFINITOR DISPERZ everolimus TABLET, FOR SUSPENSION;ORAL 203985-001 Aug 29, 2012 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis Pharm AFINITOR DISPERZ everolimus TABLET, FOR SUSPENSION;ORAL 203985-002 Aug 29, 2012 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis Pharm AFINITOR DISPERZ everolimus TABLET, FOR SUSPENSION;ORAL 203985-003 Aug 29, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis AFINITOR everolimus TABLET;ORAL 022334-003 Jul 9, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis AFINITOR everolimus TABLET;ORAL 022334-001 Mar 30, 2009 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis AFINITOR everolimus TABLET;ORAL 022334-004 Mar 30, 2012 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis AFINITOR everolimus TABLET;ORAL 022334-002 Mar 30, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis ZORTRESS everolimus TABLET;ORAL 021560-001 Apr 20, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis ZORTRESS everolimus TABLET;ORAL 021560-002 Apr 20, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis ZORTRESS everolimus TABLET;ORAL 021560-003 Apr 20, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,665,772

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9221220Oct 09, 1992
PCT Information
PCT FiledSeptember 24, 1993PCT Application Number:PCT/EP93/02604
PCT Publication Date:April 28, 1994PCT Publication Number: WO94/09010

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Farmers Insurance
Fish and Richardson
Covington
Harvard Business School
Fuji
McKesson
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot